CIRM Funded Clinical Trials

Stem-Derived IL13Ra2 Chimeric Antigen Receptor T cells for Patients with Melanoma and Advanced Solid Tumors

Disease Area:

Melanoma

Investigator:

Institution:

Stanford University

CIRM Grant:

CLIN2-14801 (Active)

Award Value:

$10,211,085.00

Trial Sponsor:

Stanford University

Trial Stage:

Phase 1

Trial Status:

Launching

Targeted Enrollment:

N/A

Subscribe to Receive CIRM News

Get the latest CIRM news, information on upcoming meetings, and funding opportunities delivered to your inbox.